Loading clinical trials...
Loading clinical trials...
Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach
The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response
A descriptive analysis of the data will be made. Means and standard deviations for continuous data frequencies for categorical data will be performed. Wilcoxon test Mann-Whitney U test Chi square will be used for frequency analysis of responders Data Analysis and Statistical Software(STATA).
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Instituto Nacional de Salud Publica
México, Cuernavaca Morelos, Mexico
Clínica Especializada CONDESA
Mexico City, D.F, Mexico
Start Date
May 1, 2010
Primary Completion Date
June 1, 2012
Completion Date
June 1, 2013
Last Updated
June 12, 2013
100
ESTIMATED participants
Isoniazid
DRUG
Lead Sponsor
Instituto Nacional de Salud Publica, Mexico
Collaborators
NCT07071623
NCT06272812
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04375800